How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

678 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use. Full Text available with Trip Pro

hydrochloride, mirtazapine, nortriptyline hydrochloride, paroxetine hydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride. As measures of assay sensitivity, additional index prescriptions examined included the antiasthma medication albuterol sulfate and the antiobesity medications orlistat, phentermine hydrochloride, and sibutramine hydrochloride. Mixed-effects models were used to estimate rate of weight change over 12 months in comparison with the reference antidepressant

2014 JAMA psychiatry (Chicago, Ill.)

162. A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

or immunomodulating agents History of severe or multiple allergies, or known allergy to soy or aprotinin. History of tobacco or nicotine use within 10 weeks prior to screening Patient is on a weight loss program and is not in the maintenance phase, or patient that started weight loss medication (e.g., orlistat or sibutramine) within 8 weeks prior to screening Pregnancy or breast-feeding Patient has a screening visit systolic blood pressure of ≥165 mmHg or diastolic blood pressure of ≥100 mmHg. Patient

2014 Clinical Trials

163. Processed Orange and the Glycemic Response

(oral or ocular) (e.g., Sotalol, Bisoprolol), beta-adrenergic drugs, calcium channel blocking agents (Amlodipine, Nicardipine), angiotensin converting enzyme (ACE) inhibitors (Captopril, Cilazapril), angiotensin receptor blocking agents (Valsartan), nitrates, diuretics (Chlortalidone), venlafaxine and sibutramine, decongestants or chloroquine Systolic blood pressure >150 mmHg and/or diastolic blood pressure >95 mmHg CVD including coronary artery disease, left ventricular hypertrophy, congestive

2014 Clinical Trials

164. Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

, ardeparin, certoparin, lepirudin, bivalirudin Other anticoagulants: argatroban, apixaban, dabigatran, rivaroxaban, warfarin, acenocoumarol, dicumarol, phenindione and other anticoagulants Lithium Selective serotonin and norepinephrine reuptake inhibitors: milnacipran, fluoxetine, paroxetine, nefazodone, citalopram, clovoxamine, escitalopram, flesinoxan, femoxetine, duloxetine, venlafaxine, vilazodone, sibutramine, desvenlafaxine Anticonvulsants: phenytoin, paraldehyde, valproic acid, carbamazepine

2014 Clinical Trials

165. Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

with attending physician) Liver disease; history of alcoholism. Known or suspected allergy to liraglutide Contraindications to liraglutide: patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 Patients with a history of pancreatitits Patients that have been treated with drugs that promote weight loss (e.g., Xenical® [orlistat], Meridia® [sibutramine], Acomplia® [rimonabant], Acutrim® [phenylpropanolamine], or similar over

2014 Clinical Trials

166. Effects of Obex in Overweight and Obese Patients

with chronic medical conditions requiring regular intake of any prescription medications. Used drugs for weight loss (e.g., Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanolamine], Accomplia [rimonabant], Alli [low-dose orlistat], or other similar over-the-counter weight loss remedies or medications) within 3 months of screening Are actively participating in, or have participated in a formal weight loss program within the last 3 months Contacts and Locations Go to Information from

2014 Clinical Trials

167. The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient

supplements, vitamins and herbal products at least 3 months before and throughout the intervention Exclusion Criteria: people who have used n-3 Fatty Acid Supplementation in last 3 months, having chronic renal disease , GI disease, Hepatobiliary diseases, hematological disorders, hypo- or hyperthyroidism, type 1 diabetes, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones. Contacts and Locations Go to No Contacts or Locations

2014 Clinical Trials

168. Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial. (Abstract)

in a large weight loss trial.Data from the Sibutramine Cardiovascular Outcomes (SCOUT) trial, including almost 10.000 overweight/obese high cardiovascular risk patients, were used. The relationship between total bilirubin level at screening and the primary outcome (i.e. non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest or cardiovascular death) for the entire study period was investigated using Cox proportional hazards models. The population was divided into four groups based

2014 Nutrition, metabolism, and cardiovascular diseases : NMCD Controlled trial quality: uncertain

169. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. (Abstract)

. Fifty overweight/obese women with PCOS were prescribed an energy-restricted diet, were instructed to exercise and were randomized to orlistat 120 mg tid or sibutramine 10 mg qd for 6 months.In normal weight women, treatment with metformin reduced the body mass index (BMI) and circulating androgens, improved markers of IR and lowered PAI-1 levels. In overweight/obese women, sibutramine and orlistat yielded comparable reductions in BMI and markers of IR. In contrast, the effects on the free androgen (...) index (FAI) differed (p=0.027): sibutramine reduced the FAI (p=0.005), whereas orlistat had no effect. The effects of sibutramine and orlistat on PAI-1 levels also differed (p=0.042): sibutramine reduced PAI-1 levels (p<0.001), whereas orlistat had no effect.Metformin and sibutramine, but not orlistat, reduce PAI-1 levels in PCOS. The reduction in circulating androgens during metformin and sibutramine treatment might be implicated in this decline.

2014 Hormones (Athens, Greece) Controlled trial quality: uncertain

170. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. (Abstract)

A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. No long-term studies have compared centrally acting drugs for treating obesity.To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss.A prospective, randomized, placebo (PCB)-controlled study conducted at a single academic institution.A total of 174 obese premenopausal women.Participants randomly

2014 International Journal of Obesity Controlled trial quality: uncertain

171. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. (Abstract)

Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in body weight and blood (...) . Post hoc subgroup analyses of weight change (categories) and blood pressure were performed overall and by treatment group (6-week sibutramine followed by randomized placebo or continued sibutramine). The primary outcome event (POE) was a composite of nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death. Time-to-event analyses of the POE were performed using Cox regression models with factors for treatment, subgroups and interactions.During the initial

2014 International Journal of Obesity Controlled trial quality: uncertain

172. Influence of eating behaviors on short-term weight loss by orlistat and anorectic agent. (Abstract)

Influence of eating behaviors on short-term weight loss by orlistat and anorectic agent. Little data exists concerning whether eating behaviors determine the response to orlistat treatment, especially with added anorectic agents. This study was a sub-investigation of a 12-week randomized controlled trial for the additive effect of orlistat on sibutramine treatment. The analysis presented here was restricted to 98 women who had fulfilled the protocol. The Dutch eating behavior questionnaire (...) in the treatment with orlistat and sibutramine. Subjects with less vulnerability to emotional cues had significantly more weight loss with orlistat treatment and anorectic agents. © 2013.

2014 Eating behaviors Controlled trial quality: uncertain

173. Change in body composition during a weight loss trial in obese adolescents. Full Text available with Trip Pro

index (BMI) change with TotFM (R = 0.70-0.91, P = 0.001) and WC change (R = 0.53-0.55, P < 0.001). Conclusions Weight loss in obese adolescents during a weight loss trial using lifestyle management and sibutramine was primarily from trunk FM. Although absolute LM increased in boys and decreased in girls, the percentage of weight that is LM increased for both boys and girls. Changes in BMI were more reflective of changes in FM than changes in WC.© 2013 The Authors. Pediatric Obesity © 2013

2014 Pediatric obesity Controlled trial quality: uncertain

174. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: Randomized placebo-controlled clinical trial of self-help and medication. Full Text available with Trip Pro

therapy (shCBT) and an anti-obesity medication (sibutramine), alone and in combination, and it is only the second placebo-controlled trial of any medication for BED to evaluate longer-term effects after treatment discontinuation. 104 obese patients with BED (73% female, 55% non-white) were randomly assigned to one of four 16-week treatments (balanced 2-by-2 factorial design): sibutramine (N = 26), placebo (N = 27), shCBT + sibutramine (N = 26), or shCBT + placebo (N = 25). Medications were (...) administered in double-blind fashion. Independent assessments were performed monthly throughout treatment, post-treatment, and at 6- and 12-month follow-ups (16 months after randomization). Mixed-models analyses revealed significant time and medication-by-time interaction effects for percent weight loss, with sibutramine but not placebo associated with significant change over time. Percent weight loss differed significantly between sibutramine and placebo by the third month of treatment and at post

2014 Behaviour research and therapy Controlled trial quality: predicted high

177. Unstable Angina (Diagnosis)

. Safety: Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. US Food and Drug Administration. October 8, 2010. Available at . Accessed: June 5, 2013. Soukoulis V, Boden WE, Smith SC Jr, O'Gara PT. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res . 2014 Jun 6. 114(12):1944-58. . . Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical

2014 eMedicine.com

180. Stimulants (Overview)

) Phentermine - Fastin, Ionamin, Adipex Pipradrol Sibutramine - Meridia (withdrawn from US market October 8, 2010) Schedule V These substances have an abuse potential less than those in schedule IV. Schedule V controlled substances consist of preparations containing limited quantities of certain narcotic drugs and are generally for antitussive and antidiarrheal purposes. These drugs are subject to state and local regulation, and a prescription may not be required. Schedule V stimulants include pyrovalerone (...) to stop sales and marketing of pemoline. Sibutramine (Meridia) is a combination serotonin and norepinephrine and dopamine reuptake inhibitor whose appetite-suppressive effects appear to be related to its noradrenergic action. When its noradrenergic activity is blocked, the appetite suppression is lost. Selective serotonin reuptake inhibitors cause initial transient anorexia without causing long-term weight loss. Sibutramine is no longer marketed. On October 8, 2010, Abbott and the US Food and Drug

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>